Glesatinib
Glesatinib is an experimental anti-cancer drug.
It is in phase 2 clinical trials for non-small cell lung cancer.
It is a spectrum selective tyrosine kinase inhibitor "for the treatment of non-small cell lung cancer patients with genetic alterations of MET".